I provide independent and original analysis, pricing metrics and recommendations for the stem, cell, gene and regenerative therapy equities.

Biostage (BSTG) raised $4 M with sale of 60 M shares with 100% warrant coverage

December 14, 2017

What about past shareholders; don’t they deserve to know where $30 M in three years went..?

Biostage (BSTG) de-listing determination

December 7, 2017

Effective at the opening of the trading session on December 18, 2017 as communicated 12/7/17 Another shovel of dirt to its grave, shame on them ... incompetance at its worst!

Biostage (BSTG) the end is in sight with a lab liquidation auction, next the lights get turned off

December 6, 2017

$30 M of shareholder monies down the drain by a “gang that couldn’t talk “straight” or execute Where are “these” dollars going, certainly NOT to shareholders who are left with an empty bag!

Roll Call

The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.